In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

New danger? Popular weight loss drugs and diabetes medications may trigger permanent eye damage! New study raises serious ...

PATIENTS taking blockbuster diabetes and weight loss drugs are waking up with vision loss, researchers warn. Some reported ...

Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder characterized by a near-total absence of ...

If you continue to have this issue please contact customerservice@slackinc.com. Adults receiving tirzepatide in the SURPASS trials had significant decreases in urine albumin-to-creatinine ratio.

Health experts are investigating a possible link between popular weight loss drugs like Ozempic and sudden blindness.

At least nine patients using the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and tirzepatide developed ophthalmic complications, of whom seven had nonarteritic anterior ischemic ...

A weekly diabetes medication may replace painful daily hormone injections for patients with congenital generalised lipodystrophy (CGL). Early findings suggest that tirzepatide – used for diabetes and ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio than those receiving comparators such as placebo or another therapy ...